Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; sodium starch glycollate; colloidal anhydrous silica; magnesium stearate; hypromellose; purified talc; macrogol 4000; titanium dioxide - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin, quantity: 250 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; sodium starch glycollate; colloidal anhydrous silica; magnesium stearate; hypromellose; purified talc; macrogol 4000; titanium dioxide - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - ciprofloxacin hydrochloride 291mg equivalent ciprofloxacin 250 mg;   - film coated tablet - 250 mg - active: ciprofloxacin hydrochloride 291mg equivalent ciprofloxacin 250 mg   excipient: colloidal silicon dioxide hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - ciprofloxacin hydrochloride 582mg equivalent ciprofloxacin 500 mg;   - film coated tablet - 500 mg - active: ciprofloxacin hydrochloride 582mg equivalent ciprofloxacin 500 mg   excipient: colloidal silicon dioxide hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - ciprofloxacin hydrochloride 873mg equivalent ciprofloxacin 750 mg;   - film coated tablet - 750 mg - active: ciprofloxacin hydrochloride 873mg equivalent ciprofloxacin 750 mg   excipient: colloidal silicon dioxide hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

Canada - English - Health Canada

sanis health inc - ciprofloxacin (ciprofloxacin hydrochloride) - tablet - 250mg - ciprofloxacin (ciprofloxacin hydrochloride) 250mg - quinolones

Canada - English - Health Canada

sanis health inc - ciprofloxacin (ciprofloxacin hydrochloride) - tablet - 500mg - ciprofloxacin (ciprofloxacin hydrochloride) 500mg - quinolones

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

hankook korus pharm co. - ciprofloxacin (ciprofloxacin hydrochloride) - tablets film-coated - 500mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

hankook korus pharm co. - ciprofloxacin (ciprofloxacin hydrochloride) - tablets film-coated - 500mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 873.32 mg (equivalent: ciprofloxacin, qty 750 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; pregelatinised maize starch; crospovidone; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - apx-ciprofloxacin is indicated for the treatment of infections caused by susceptible organisms in the conditions listed: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be preformed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated beforeresults of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-postitive aerobic bacteria. if anaerobic organisms are suspected as accompanying agents, additional therapy should be considered.